

The
United
States
of
America



**The Director of the United States
Patent and Trademark Office**

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Michelle K. Lee

Deputy Director of the United States Patent and Trademark Office



US008802433B2

(12) **United States Patent**
Moriya et al.

(10) **Patent No.:** **US 8,802,433 B2**
(45) **Date of Patent:** **Aug. 12, 2014**

(54) **MACROPHAGE
PHAGOCYTOSIS-ACTIVATING
COMPOSITION AND/OR COMPOSITION
PROMOTING CYTOKINE PRODUCTION IN
MACROPHAGES**

(75) Inventors: **Naoyuki Moriya, Kimitsu (JP); Yukiko
Moriya, Kimitsu (JP); Yasuhiro
Nikawa, Kimitsu (JP); Yukitoshi
Nagahara, Hatoyama-machi (JP);
Hidekazu Tamegai, Hatoyama-machi
(JP); Tadaaki Miyazaki, Sapporo (JP)**

(73) Assignee: **Aureo Co., Ltd., Tokyo (JP)**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/512,502**

(22) PCT Filed: **Dec. 3, 2010**

(86) PCT No.: **PCT/JP2010/071747**

§ 371 (c)(1),
(2), (4) Date: **Sep. 11, 2012**

(87) PCT Pub. No.: **WO2011/068226**

PCT Pub. Date: **Jun. 9, 2011**

(65) **Prior Publication Data**

US 2012/0329154 A1 Dec. 27, 2012

(30) **Foreign Application Priority Data**

Dec. 3, 2009 (JP) 2009-275553

(51) **Int. Cl.**

C12N 5/07 (2010.01)
A61K 31/4745 (2006.01)
A61K 31/513 (2006.01)
C12R 1/645 (2006.01)
C12N 1/38 (2006.01)
A61K 36/06 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/4745** (2013.01); **A61K 31/513**
(2013.01); **C12R 1/645** (2013.01); **C12N 1/38**
(2013.01); **A61K 36/06** (2013.01)
USPC **435/375; 424/1.41; 424/102; 424/41;**
424/343

(58) **Field of Classification Search**

CPC **C12N 2310/321; C12N 2310/3521;**
C12N 2310/14; C12N 15/1138; C12N 15/1111;
C12N 2310/3525; C12N 15/113; C12N
15/1131; C12N 1/38; C12N 2310/322; C12N
2310/3231; C12N 2310/331; C12N 2320/30;
C12N 2320/51; C12N 2760/16111
USPC **435/375; 424/1.41, 41, 373**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2002/0082418 A1 6/2002 Ikewaki et al.
2004/0076633 A1* 4/2004 Thomsen et al. 424/184.1
2005/0235372 A1 10/2005 Akira et al.
2005/0257280 A1 11/2005 Akira
2005/0271613 A1 12/2005 Suzuki et al.
2006/0105048 A1 5/2006 Terada et al.
2009/0060870 A1 3/2009 van der Burg et al.
2009/0060889 A1 3/2009 von Hofe et al.
2009/0123493 A1 5/2009 Ataman-Onal
2010/0068184 A1 3/2010 Moriya et al.
2010/0178354 A1 7/2010 Terada

FOREIGN PATENT DOCUMENTS

JP 2000-247884 9/2000
JP 2002-204687 A 7/2002
JP 2004-073073 A 11/2004
JP 2006-104439 A 4/2006
JP 2007-063287 A 3/2007
JP 3947999 7/2007
JP 2008-539228 A 11/2008
JP 2009-515859 A 4/2009
WO WO03/043588 A1 5/2003
WO WO2007/069468 A1 6/2007
WO WO2008/053728 A1 5/2008
WO WO2008/112218 A2 9/2008

OTHER PUBLICATIONS

Colombo, Mario et al. Interleukin-12 in anti-tumor immunity and immunotherapy. *Cytokine & Growth Factor Reviews* 13. 2002. pp. 155-168.*

Daiso Co. JP 2006-104439A. 2006. Machine Translated from the JPO website on May 15, 2013.*

Tomai, Mark et al. The Immune Response Modifiers Imiquimod and R-848 Are Potent Activators of B Lymphocytes. *Cellular Immunology* 203. 2000. pp. 55-65.*

(Continued)

Primary Examiner — Susan Hanley

Assistant Examiner — Nghi Nguyen

(74) *Attorney, Agent, or Firm* — RatnerPrestia

(57) **ABSTRACT**

Disclosed is a highly effective macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages using an active component derived from natural products. A culture obtained by culturing microorganisms belonging to the genus *Aureobasidium* (*Aureobasidium* sp.) is used as the active component of the macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages. By means of the macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages, macrophage phagocytosis can be activated, and cytokine production in macrophages can be promoted. In particular, a macrophage phagocytosis-activating composition can activate the phagocytosis of cancer cells or cells damaged or destroyed by anticancer drugs.

1 Claim, 7 Drawing Sheets